Arcutis Biotherapeutics
ARQT
93 hedge funds and large institutions have $925M invested in Arcutis Biotherapeutics in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 40 increasing their positions, 19 reducing their positions, and 21 closing their positions.
345% more call options, than puts
Call options by funds: $1.38M | Put options by funds: $311K
111% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 19
1.23% more ownership
Funds ownership: 90.96% → 92.19% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
10% less funds holding
Funds holding: 103 → 93 (-10)
12% less capital invested
Capital invested by funds: $1.05B → $925M (-$130M)
43% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$13M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$4.98M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$4.68M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$4.07M |
| 5 |
BlackRock
New York
|
+$2.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$12.6M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$10.4M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$10.3M |
| 4 |
ACM
Altium Capital Management
New York
|
-$6.09M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.9M |
ARQT Hedge Fund Activity: Q4 2021 in Review
93 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q4 2021, worth a combined $925M — down 12% from $1.05B a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ARQT and 12 opened new positions — a net loss of 9 holders — while 19 trimmed existing stakes and 40 added.
The largest buyer was Point72 Asset Management, adding an estimated $13M. The largest seller was Wells Fargo, cutting an estimated $12.6M.
- 93 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q4 2021, down from 103 in Q3 2021.
- Funds reported $925M of Arcutis Biotherapeutics stock for Q4 2021, down 12% quarter-over-quarter.
- 12 funds opened new Arcutis Biotherapeutics positions in Q4 2021 and 21 closed out, a net change of -9 holders.
- The largest Arcutis Biotherapeutics buyer in Q4 2021 was Point72 Asset Management, an estimated $13M added.
- The largest Arcutis Biotherapeutics seller in Q4 2021 was Wells Fargo, an estimated $12.6M sold.
Based on aggregated 13F filings for Q4 2021.